PRAC Valproate, Middle East HTA, Canada Pricing, RWE Latin America, Asia Gene Therapy

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: PRAC valproate conclusions, HTA methodological updates in the Middle East, Canadian pricing policy developments, RWE integration challenges in Latin America, and gene therapy HEOR strategies in Asia. Let's get into it.

MarcusPRAC valproate conclusions. The committee finalized its review on paternal exposure risks, reinforcing pharmacovigilance methodologies for teratogenic substances. HTA bodies will likely reference these conclusions in risk-sharing agreements, especially for drugs with long-term generational impacts. The procedural clarity here sets a precedent for future safety reviews.

SaraPrecedent is one thing, operational impact another. HTA agencies haven't integrated paternal exposure into cost-effectiveness models. How do you quantify generational risk in QALYs? PRAC conclusions create evidence gaps for value assessments. Real-world data on paternal outcomes is scarce, forcing payers to rely on theoretical modeling. That’s not evidence-driven strategy.

MarcusTheoretical modeling is better than ignoring the risk entirely. PRAC provides a scientific anchor—HTA bodies can build from there. Avoiding the issue because RWE is limited isn’t a solution. It’s a challenge to generate better data, not to dismiss the evidence.

SaraGenerate data how? Manufacturers won’t fund paternal exposure studies without regulatory pressure. And HTA bodies can’t mandate that. This is a structural disconnect between pharmacovigilance and value frameworks. PRAC conclusions alone won’t bridge it.

MarcusMoving to HTA methodological updates in the Middle East. Gulf HTA agencies are adopting hybrid cost-effectiveness thresholds, blending local epidemiology with international benchmarks. This reflects regional disease burdens and healthcare system constraints. It’s a pragmatic adaptation.

SaraPragmatic or inconsistent? Hybrid thresholds create comparability issues across jurisdictions. If Saudi Arabia uses a different threshold than Bahrain, how do manufacturers prioritize evidence generation? It fragments regional collaboration. Consistency should precede adaptation.

MarcusConsistency isn’t always feasible. Local epidemiology demands tailored thresholds. The alternative is applying Western thresholds to populations with different disease profiles, which distorts value. Flexibility here is strength, not fragmentation.

SaraFlexibility without standardization undermines cross-border submissions. Manufacturers face moving targets. That increases development costs and delays access. Middle East HTA needs harmonized frameworks first, then regional adjustments.

MarcusCanadian pricing policy developments. Canada’s new reference pricing model for biologics expands to include therapeutic comparators, not just identical molecules. This shifts value arguments toward clinical differentiation over price alone. A significant evolution.

SaraSignificant but problematic. Reference pricing based on therapeutic comparators undervalues innovation. If a new biologic offers better safety or adherence, but isn’t priced identically, it gets penalized. That disincentivizes R&D. Canada’s model prioritizes cost containment over therapeutic advancement.

MarcusCost containment is inevitable. The model rewards manufacturers who demonstrate clear clinical superiority. If your product isn’t meaningfully better, why should it command a premium? That’s market access 101.

SaraMarket access isn’t just about premiums—it’s about patient access. Reference pricing squeezes margins, forcing manufacturers to either underinvest in evidence or withdraw. Canada’s approach risks stifling innovation in high-need areas.

MarcusRWE integration challenges in Latin America. HTA agencies struggle with data quality in real-world evidence submissions, particularly in decentralized trials. Regulatory acceptance remains low outside of Brazil and Mexico. A bottleneck for evidence generation.

SaraLow acceptance isn’t just about quality—it’s about capacity. Latin American HTA bodies lack infrastructure to analyze complex RWE. They default to RCTs because they understand them. Until that capacity builds, RWE will remain supplemental at best.

MarcusCapacity can be built through federated networks. DARWIN EU’s model could be adapted locally. The challenge is willingness, not feasibility. HTA bodies must embrace RWE as a primary tool, not a backup.

SaraWillfulness requires investment. Who funds that training? Manufacturers? Governments? Without clear mandates, RWE integration stays aspirational. Latin America needs policy-led frameworks, not just technical solutions.

MarcusGene therapy HEOR strategies in Asia. Japan and Singapore are developing value frameworks for ultra-high-cost therapies, focusing on long-term budget impact modeling. Asia-Pacific HTA collaboration is accelerating around this issue. A necessary response to $2M+ price tags.

SaraBudget impact modeling ignores equity. How do you justify a gene therapy for rare diseases in a country with limited pediatric oncology infrastructure? Asia’s frameworks risk becoming cost-containment tools, not access enablers. Patient outcomes should drive value, not just fiscal projections.

MarcusEquity doesn’t negate financial sustainability. If a therapy bankrupts a healthcare system, it’s accessible to no one. Budget impact modeling ensures these treatments remain viable long-term. It’s a balance.

SaraBalance requires shared risk. Asia-Pacific HTA hasn’t adopted outcomes-based agreements at scale. Without them, budget impact models are theoretical. Gene therapy access needs innovative payment models, not just better math.

MarcusSara makes valid points on equity, but frameworks must evolve practically. Sara counters that pragmatism shouldn’t compromise access. We’ll monitor how these tensions play out.

SaraMarcus emphasizes evidence-based thresholds, but regional fragmentation undermines strategy. Marcus argues flexibility reflects local realities. Disagreements remain unresolved.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.